Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1007/s13577-021-00495-2

http://scihub22266oqcxt.onion/10.1007/s13577-021-00495-2
suck pdf from google scholar
33527306!7849963!33527306
unlimited free pdf from europmc33527306    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33527306      Hum+Cell 2021 ; 34 (2): 698-699
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • mTOR inhibition: a double-edged sword in patients with COVID-19? #MMPMID33527306
  • Ghasemnejad-Berenji M
  • Hum Cell 2021[Mar]; 34 (2): 698-699 PMID33527306show ga
  • The current COVID-19 is one of the deadliest pandemics in recent decades. In the lack of a specific treatment for this novel infection, knowing the role of cell signaling pathways in the pathogenesis of this infection could be useful in finding effective drugs against this disease. The mammalian or mechanistic target of rapamycin (mTOR) is an important cell signaling pathway that has important role in the regulation of cell growth, protein synthesis, and metabolism in reactance to upstream signals in both pathological and normal physiological conditions. Recently, some researchers have suggested the therapeutic potential of mTOR inhibitors such as rapamycin against COVID-19. However, it is important to consider the role of activation of this pathway in controlling immune system response against viral activity in drug repositioning of rapamycin and other mTOR inhibitors in SARS-CoV-2 infection.
  • |*COVID-19 Drug Treatment[MESH]
  • |*Drug Repositioning[MESH]
  • |COVID-19/immunology[MESH]
  • |Humans[MESH]
  • |Immune System/*immunology[MESH]
  • |Signal Transduction/*genetics/physiology[MESH]
  • |Sirolimus/*pharmacology/*therapeutic use[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box